Literature DB >> 2158398

Chromosome analysis of 31 Wilms' tumors.

W W Sheng1, S Soukup, K Bove, B Gotwals, B Lampkin.   

Abstract

Cytogenetic analysis was done on 31 Wilms' tumors, including 2 renal tumors of clear cell sarcoma type, using short term cultures of primary tumors and/or nude mouse passages. Nonrandom secondary chromosome abnormalities, in particular, were noted as evidence of clonal evolution. Apparently normal karyotypes were found in 5 Wilms' tumors, all in patients less than or equal to 22 months old, and in one clear cell sarcoma. Abnormal karyotypes were seen in 25 tumors (80%); 6 were pseudodiploid, 3 were hypodiploid, and 16 (52%) were hyperdiploid, of which 8 had a modal number of 47-49 and 8 had a modal number of 50-55. Nonrandom structural abnormalities involved 1p/1q, 11p, 7p/7q, 16p/16q, 12q, and 17p/17q. Nonrandom numerical abnormalities included +6, +8, and +18. Trisomy 12 was the most common abnormality, structural or numerical, seen in 52% of tumors (81% of the hyperdiploid). In 2 tumors the +12 was the only apparent abnormality; in 1 other tumor an i(12q) was seen, suggesting that +12 may have special significance in the clonal progression of Wilms' tumor. Informative karyotypes of 68 Wilms' tumors from other reports were reviewed and compared to results in this series.

Entities:  

Mesh:

Year:  1990        PMID: 2158398

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  renal tumors and tumor-like lesions in pediatric patients.

Authors:  J M Kissane; L P Dehner
Journal:  Pediatr Nephrol       Date:  1992-07       Impact factor: 3.714

2.  High-resolution genomic profiling of an adult Wilms' tumor: evidence for a pathogenesis distinct from corresponding pediatric tumors.

Authors:  Jenny Karlsson; Linda Holmquist Mengelbier; Peter Elfving; David Gisselsson Nord
Journal:  Virchows Arch       Date:  2011-09-23       Impact factor: 4.064

Review 3.  Alteration of WWOX in human cancer: a clinical view.

Authors:  Izabela Baryła; Ewa Styczeń-Binkowska; Andrzej K Bednarek
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-13

4.  Clear cell sarcoma of the kidney demonstrates an embryonic signature indicative of a primitive nephrogenic origin.

Authors:  Jenny Karlsson; Linda Holmquist Mengelbier; Cristina D Ciornei; Arlene Naranjo; Maureen J O'Sullivan; David Gisselsson
Journal:  Genes Chromosomes Cancer       Date:  2014-02-01       Impact factor: 5.006

Review 5.  Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour.

Authors:  R H Scott; C A Stiller; L Walker; N Rahman
Journal:  J Med Genet       Date:  2006-05-11       Impact factor: 6.318

6.  [Congenital urogenital malformations associated with nephroblastomas. Long-term results of a study in Erlangen].

Authors:  V Zugor; D Krot; G E Schott
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639

7.  Chromosome aberrations in mesoblastic nephroma.

Authors:  D E Schofield; E J Yunis; J A Fletcher
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

8.  Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.

Authors:  E Cristy Ruteshouser; Stephen M Robinson; Vicki Huff
Journal:  Genes Chromosomes Cancer       Date:  2008-06       Impact factor: 5.006

9.  Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression.

Authors:  M Nemani; G Linares-Cruz; H Bruzzoni-Giovanelli; J P Roperch; M Tuynder; L Bougueleret; D Cherif; M Medhioub; P Pasturaud; V Alvaro; H der Sarkissan; L Cazes; D Le Paslier; I Le Gall; D Israeli; J Dausset; F Sigaux; I Chumakov; M Oren; F Calvo; R B Amson; D Cohen; A Telerman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

10.  Genome-wide loss of maternal alleles in a nephrogenic rest and Wilms' tumour from a BWS patient.

Authors:  P R Hoban; J Heighway; G R White; B Baker; J Gardner; J M Birch; P Morris-Jones; A M Kelsey
Journal:  Hum Genet       Date:  1995-06       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.